article · Pharmaceutical Development and Technology
results confirmed the superior effects on tumor growth inhibition (90.01%), pain remission, and bone tumor markers of NC4 over NC*. NC4 showed an absence of kidney and liver toxicity. In conclusion, these comprehensive findings strongly support the clinical relevance of NC4 in treating bone metastasis. Its ability to passively target the drug, inhibit tumor growth, alleviate pain, and exhibit favorable biomarker profiles and safety make it a promising candidate for improving the management and outcomes of patients with bone metastasis.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/10837450.2025.2574082
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
